Furthermore, to validate the predictive role of DRGs risk scoring in immune therapy response in clinical tissue samples of SARC, we examined 24 advanced sarcoma patients receiving anti-PD-1/PD-L1 treatment. Here, PDCD1 is linked to sarcoma.